Noom Introduces Innovative In-App Body Scan Technology to Monitor Muscle-Mass Retention During GLP-1 Treatment
17 oct. 2024 08h02 HE
|
Noom Inc
Noom announced that it is expanding its in-app capabilities to include a revolutionary body scan feature.
Sesame, America’s Low-Cost Leader in Healthcare, Is First Major Direct-to-Consumer Weight Loss Company to Offer Compounded Semaglutide to All 50 United States
16 oct. 2024 08h05 HE
|
Sesame
NEW YORK CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced that it has begun offering...
Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
16 oct. 2024 05h30 HE
|
Neurogastrx
Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists
Yalda Olcott, PharmD, Joins Noom as Head of Healthcare and Pharmacy Operations
01 oct. 2024 08h02 HE
|
Noom Inc
Noom announces the appointment of Yalda Olcott, PharmD, as Head of Healthcare and Pharmacy Operations.
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
01 oct. 2024 07h00 HE
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence
30 sept. 2024 22h00 HE
|
LeaderMed Group; Combiphar
LeaderMed and Combiphar form a joint venture to tackle Indonesia’s diabetes and obesity crisis with LM-008 and UltraSculpt, launching a Phase 3 trial.
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
25 sept. 2024 08h30 HE
|
Entera Bio Ltd.; OPKO Health, Inc.
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
24 sept. 2024 07h02 HE
|
Noom Inc
Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications.
Noom Appoints Rachel Mahoney as Chief Brand Officer
17 sept. 2024 08h02 HE
|
Noom Inc
Noom is pleased to announce the appointment of Rachel Mahoney as Chief Brand Officer.
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
12 sept. 2024 08h03 HE
|
Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.